Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
2.
Ann Allergy Asthma Immunol ; 127(4): 462-470.e2, 2021 10.
Article in English | MEDLINE | ID: mdl-33895419

ABSTRACT

BACKGROUND: Substantial discrepancies among anaphylaxis severity scores may delay epinephrine administration. OBJECTIVE: The study aims to develop a transparent severity grading system of food-induced acute allergic reactions with a decision model for epinephrine use. METHODS: The natural course of 315 acute food-induced allergic reactions in children hospitalized at the Allergology department between May 2016 and July 2019 owing to follow-up treatment and allergy diagnostics was evaluated. The severity of episodes was classified according to the 5 most accepted grading systems. The interrater reliability of classification between anaphylaxis severity scores was assessed. All symptoms were grouped into a heat map according to their real-life incidence and clinical relevance. Based on the heat map analysis, a severity grading system of food-induced acute allergic reactions in children with the epinephrine administration decision model was created. RESULTS: Data from 259 food-induced anaphylaxis episodes in 157 children were included in the analysis. Comparing the grading systems, we observed a 24.7% to 70.2% disagreement between severity scores. The heat map illustrated a strong association between 29 symptoms and their categorization. A new severity grading system was developed and a 2-stage decision model was proposed: "epinephrine yes" (any rapidly progressing symptoms, even mild ones or from 1 organ system; any symptoms from more than 1 organ system; or every grade of anaphylaxis), and "epinephrine available and prepared to use" (nonprogressing mild systemic allergic reaction from 1 system area only; no anaphylaxis). CONCLUSION: A new severity grading system of food-induced acute allergic reactions in children could serve as a clinical tool for health care professionals to avoid epinephrine administration delay.


Subject(s)
Decision Support Techniques , Epinephrine/therapeutic use , Food Hypersensitivity/diagnosis , Food Hypersensitivity/drug therapy , Severity of Illness Index , Adolescent , Allergens/immunology , Anaphylaxis/diagnosis , Anaphylaxis/drug therapy , Anaphylaxis/pathology , Child , Child, Preschool , Epinephrine/administration & dosage , Female , Food Hypersensitivity/pathology , Humans , Infant , Infant, Newborn , Male
4.
Allergy ; 74(10): 1945-1955, 2019 10.
Article in English | MEDLINE | ID: mdl-31131460

ABSTRACT

BACKGROUND: Food allergy in children can be life-threatening. Component-resolved diagnostics approach to food anaphylaxis is rarely assessed in children. The aim of the study was to identify the food allergen components as the triggers responsible for severe anaphylaxis, with regard to characteristics and associated risks, among children in a large, population-based setting. METHODS: Two hundred and seventy-one children who were hospitalized due to systemic allergic reaction (SAR) and food anaphylaxis were recruited. Medical history was assessed, and culprit allergen source and anaphylaxis severity grade were established. Specific IgE to 112 allergen components using multiplex ImmunoCAP ISAC immunoassay and specific IgE to hazelnut, Cor a 14, and cashew, Ana o 3, using singleplex ImmunoCAP immunoassay were determined. RESULTS: We analyzed data from 237 SAR/anaphylaxis in 237 children. Trigger at allergen component level was defined for every episode. The most common triggers of SAR/anaphylaxis were seeds (50.6%), among them, the storage proteins. Anaphylaxis triggered by Ana o 3, 2S albumin from cashews (aOR = 15.0; 95% CI: 3.27 to 73.47); Tri a 19 from wheat (aOR = 9.93; 95% CI: 1.73 to 56.97); and Cor a 9 from hazelnut (aOR = 6.53; 95% CI: 1.16 to 36.72) had the worst clinical presentation including cardiovascular and severe respiratory symptoms (grade IV-V vs I-III in Cox scale). Thirteen out of 237 (5.5%) SAR/anaphylaxis patients were triggered by Ana o 3. Almost 82% of patients with severe Ana o 3 anaphylaxis were sensitized only to this component and had no concomitant food sensitization. CONCLUSION: Monosensitization to Ana o 3 is, irrespective of other parameters, connected with high risk of severe anaphylaxis.


Subject(s)
Anaphylaxis/diagnosis , Anaphylaxis/immunology , Antigens, Plant/immunology , Food Hypersensitivity/diagnosis , Food Hypersensitivity/immunology , Plant Proteins/immunology , Adolescent , Age Factors , Child , Child, Preschool , Female , Humans , Immunization , Immunoglobulin E/immunology , Incidence , Infant , Infant, Newborn , Male
5.
Dermatol Ther ; 31(5): e12635, 2018 09.
Article in English | MEDLINE | ID: mdl-30216603

ABSTRACT

Bullous pemphigoid is the most common autoimmune blistering disorder in the elderly. It affects people aged 70 years or older. Clinically it is characterized by intensely pruritic eruption consisting of widespread tense blisters on an erythematous background. It is associated with cellular and humoral responses against hemidesmosomal components of the skin and mucous membranes. In contrast, infantile bullous pemphigoid is exceedingly rare disease and presents with some unique features like favorable prognosis, possible association with vaccination, and primary involvement of acral surfaces. Herein, we present a case of 4,5-month-old infant with neonatal pemphigoid, successfully treated with a combination of intravenous immunoglobulins and pulse methylprednisolone.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , Methylprednisolone/therapeutic use , Pemphigoid, Bullous/drug therapy , Diphtheria-Tetanus-Pertussis Vaccine/adverse effects , Drug Therapy, Combination , Female , Haemophilus Vaccines/adverse effects , Humans , Infant , Pemphigoid, Bullous/etiology , Poliovirus Vaccine, Inactivated/adverse effects , Vaccines, Combined/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL